Beijing Luzhu Biotechnology Co (HKSE:02480) EPS without NRI: HK$-0.81 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02480 Beijing Luzhu Biotechnology Co Ltd HKSE:02480
24 GF Score
Price HK$14.00
! 3 Warning Signs
View Full Analysis

What is Beijing Luzhu Biotechnology Co EPS without NRI?

Beijing Luzhu Biotechnology Co HKSE:02480 24 EPS without NRI is HK$-0.81 as of Dec. 2025. GuruFocus rates HKSE:02480 with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 1,166 Biotechnology companies, Beijing Luzhu Biotechnology Co ranks better than 78.56% on this metric.

Beijing Luzhu Biotechnology Co's earnings per share without non-recurring items for the six months ended in Dec. 2025 was HK$-0.39. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.81.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Beijing Luzhu Biotechnology Co's EPS without NRI or its related term are showing as below:

HKSE:02480' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 34.3   Med: 37.95   Max: 41.6
Current: 41.6

HKSE:02480's 3-Year EPS without NRI Growth Rate is ranked better than
78.56% of 1166 companies
in the Biotechnology industry
Industry Median: 16.2 vs HKSE:02480: 41.60

Beijing Luzhu Biotechnology Co's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.82.

Beijing Luzhu Biotechnology Co's EPS (Basic) for the six months ended in Dec. 2025 was HK$-0.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.82.


Beijing Luzhu Biotechnology Co  (HKSE:02480) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Beijing Luzhu Biotechnology Co EPS without NRI Related Terms


Beijing Luzhu Biotechnology Co EPS without NRI Historical Data

* Premium members only.

The historical data trend for Beijing Luzhu Biotechnology Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co EPS without NRI Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
-3.33 -4.08 -1.43 -0.94 -0.81

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only -0.93 -0.61 -0.34 -0.42 -0.39

HKSE:02480 vs VRTX, REGN, RVMD: EPS without NRI Comparison

For the Biotechnology subindustry, Beijing Luzhu Biotechnology Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Luzhu Biotechnology Co PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Luzhu Biotechnology Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Beijing Luzhu Biotechnology Co's PE Ratio without NRI falls into.


HKSE:02480
24GF Score
Beijing Luzhu Biotechnology Co Ltd HKSE:02480
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Luzhu Biotechnology Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of HK$-0.81 mean?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a EPS without NRI of HK$-0.81 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Beijing Luzhu Biotechnology Co and its competitors. According to the industry distribution chart, Beijing Luzhu Biotechnology Co ranks #250 out of 1166 companies in the Biotechnology industry, placing it in the top 21.4%.
Is Beijing Luzhu Biotechnology Co's EPS without NRI too high?
Beijing Luzhu Biotechnology Co's current EPS without NRI is HK$-0.81. Based on the distribution chart, Beijing Luzhu Biotechnology Co ranks #250 out of 1166 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Luzhu Biotechnology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Luzhu Biotechnology Co's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Luzhu Biotechnology Co ranks #250 out of 1166 companies for EPS without NRI. This places Beijing Luzhu Biotechnology Co in the top 21% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Beijing Luzhu Biotechnology Co and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Luzhu Biotechnology Co's current EPS without NRI is HK$-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Luzhu Biotechnology Co stock overvalued right now?
Beijing Luzhu Biotechnology Co (HKSE:02480) has a current EPS without NRI of HK$-0.81. The current EPS without NRI is HK$-0.81. Beijing Luzhu Biotechnology Co's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Beijing Luzhu Biotechnology Co (HKSE:02480), the current EPS without NRI is HK$-0.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beijing Luzhu Biotechnology Co Business Description

Address No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
24GF Score

Get the complete analysis for HKSE:02480

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.00
Price